Monthly Archives: November 2011

Study of Adherence and Persistence Among Omalizumab Users Presented at ACAAI

Investigators at PHAR, LLC and Genentech, Inc. conducted research that was presented at the American College of Allergy, Asthma & Immunology 2011 Annual Scientific Meeting. Researchers found that the number of chronic conditions and respiratory comorbidities predicted adherence and persistence to omalizumab therapy.